Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 4, 2009

View Archived Issues

GSK-2126458 shows potent preclinical antitumor activity; phase I trial under way

New camptothecin conjugate evaluated in phase I trial in advanced solid tumors

FIELD trial data support beneficial effects of fenofibrate in type 2 diabetes patients

Prasugrel more effective than clopidogrel in CAD patients with type 2 diabetes

Small-molecule compound BRA-101 reduces DSS-induced murine colitis

Novel AR antagonist ZR-291 exhibits potent preclinical activity in prostate cancer

Novartis' Onbrez Breezhaler approved in E.U. for patients with COPD

Daiichi Sankyo reports results from Q2 of 2009, ended September 30

Vertex reports results from third quarter of 2009

MicroDose Therapeutx acquires EPX-16006 from Epix

Johnson & Johnson submits NDA to FDA for tapentadol ER tablets for chronic pain

New recombinant Xyntha now available in Canada

Stryker agrees to acquire Ascent Healthcare Solutions

DiaMedica expands into neurological disorders through acquisition of Sanomune

Pacira reports results of phase III Exparel trial in postoperative pain

Roche reports encouraging results from phase III trials of taspoglutide in diabetes

Javelin submits NDA to FDA for Dyloject for acute moderate to severe pain in adults

Watson Pharmaceuticals acquires Arrow Group

Bayer Schering Pharma claims novel series of adenosine A1 agonists

Novel antibacterial agents disclosed by AstraZeneca

Merck & Co. describes beta3-adrenoceptor agonists for urinary incontinence

Agreement reached on U.S. approval pathway for Pompe disease treatment

Endo provides regulatory update on Aveed for men with low testosterone

FDA approves AstraZeneca's Seroquel for pediatric schizophrenia and bipolar mania

ExonHit Therapeutics launches AclarusDx Alzheimer's test

Epigallocatechin gallate possibly beneficial in open-angle glaucoma patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...